Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intestinal Micro-organisms in the Pathogenesis of NASH and the Effect of Doxycycline
2006-001774-24Phase 2Unknown
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxycycline in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoint: Eradication of systemic endotoxaemia. Status: unknown.
02
Drugs
doxycycline
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2006-001774-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001774-24.